Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy.

Chorn N

Department of Medicine, University of California, Los Angeles, USA. nchorn@mednet.ucla.edu

PURPOSE/OBJECTIVES: To review the clinical significance, methods of testing, and outcomes of trastuzumab (Herceptin) treatment for HER2 gene amplification and HER2 protein overexpression in breast cancer. DATA SOURCES: Published articles and abstracts, online resources, a clinical handbook, and product information. DATA SYNTHESIS: HER2 gene amplification or HER2 protein overexpression can be found in 20%-25% of breast cancers and is important pathogenic and prognostic information. HER2 also predicts patient response to trastuzumab. Patients with HER2-positive metastatic breast cancer benefit from trastuzumab whether selected by immunohistochemistry, which measures the HER2 protein, or fluorescence in situ hybridization (FISH), which measures the HER2 oncogene. However, patients who are identified accurately as HER2 gene-amplified by FISH derive the greatest benefit. CONCLUSIONS: Accurate testing is crucial for appropriate identification of patients for trastuzumab therapy. FISH is the most reproducible and accurate method. IMPLICATIONS FOR NURSING: Education regarding HER2 testing and trastuzumab helps patients to make informed decisions and facilitates active participation in their care as well as enhances dialogue with physicians.

Published 6 March 2006 in Oncol Nurs Forum, 33(2): 265-72.
Full-text of this article is available online (may require subscription).

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.